PharmaCorp International   CONFIDENTIAL
ONCOLOGY / Advanced NSCLC   Final
Study PC-2025-001   Data Cut-off: 2025-09-30

Table 14.1.1
Summary of Demographics and Baseline Characteristics
Baseline Biomarker 1 (BMRKR1) by Geographic Region
Safety Analysis Set

	Region	n	BMRKR1
A: Drug X	Africa	8	6.47 (4.70)
	Asia	91	6.00 (3.32)
	Eurasia	5	4.88 (1.61)
	Europe	4	5.44 (4.48)
	North America	13	6.84 (4.92)
	South America	13	5.18 (3.51)
B: Placebo	Africa	7	4.65 (1.92)
	Asia	94	5.97 (3.53)
	Eurasia	8	6.35 (3.89)
	Europe	3	4.17 (0.47)
	North America	15	4.21 (1.62)
	South America	7	6.22 (3.44)
C: Combination	Africa	11	6.57 (3.24)
	Asia	83	5.44 (3.53)
	Eurasia	6	3.58 (0.87)
	Europe	2	2.35 (0.42)
	North America	20	6.26 (4.13)
	South America	10	6.62 (2.71)

Note: BMRKR1 values shown as Mean (SD).

Source: ADSL dataset random.cdisc.data
Program: table_posit.R, 2025-10-02 21:50 CEST